Table 1.
Included randomized controlled clinical trials characteristics.
| Studies |
Design+ Locations |
Study period | Treatment | Control | Total no. | Primary outcome | Treatment | Control | p -value |
|---|---|---|---|---|---|---|---|---|---|
| Tamazini et al. (19) | Multicentered; 41 ICUs in Brazil | April 17-Juen 23, 2020 | 20 mg of dexamethasone/day for 5 days; 10 mg of dexa. For 5 days + Usual care | Usual care | N = 299 | Ventilator-free during the first 28 days | 54/151 | 43/148 | 0.002 |
| Group et al. (11) | RECOVERY trail 176 NHSO in the UK | March 19-June 8, 2020 | Oral or intravenous dexa. At a dose of 6 mg/day for 10 days | Usual care | N = 6,425 | 28-day mortality | 482/2104 | 1110/4321 | <0.001 |
| Jamaati et al. (18) | Iran | Intravenous dexa. At a dose of 20 mg/day for 5 days 10 mg/day for 5days | Usual care | N = 50 | Non-invasive ventilation | 9/9 | 10/10 | 0.500 | |
| Edalatifard et al. (16) | Iran | April 20-June 20, 2020 | Intravenous injection methylprednisolone 250 mg/day for 3 days | Usual care | N = 68 | Recovery | 32/34 | 16/34 | <0.001 |
| Jeronimo et al. (17) | Western Brazilian Amazon | April 18-June 16, 2020 | Intravenous MP (0.5 mg/kg) | Placebo | N = 393 | 28-day mortality | 72/194 | 76/199 | 0.629 |